These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35510210)

  • 1. Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.
    Zanwar S; Abeykoon JP
    Ther Adv Hematol; 2022; 13():20406207221093962. PubMed ID: 35510210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current approach to Waldenström Macroglobulinemia.
    Ravi G; Kapoor P
    Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenström macroglobulinemia: biology, genetics, and therapy.
    Paludo J; Ansell SM
    Blood Lymphat Cancer; 2016; 6():49-58. PubMed ID: 31360080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current approach to Waldenström macroglobulinemia.
    Kapoor P; Rajkumar SV
    Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
    Kapoor P; Paludo J; Abeykoon JP
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Treatment of Waldenström Macroglobulinemia.
    Durot E; Tomowiak C
    Curr Oncol Rep; 2023 Nov; 25(11):1375-1386. PubMed ID: 37855849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
    Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
    Varettoni M; Matous JV
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.
    Tam CS; Kapoor P; Castillo JJ; Buske C; Ansell SM; Branagan AR; Kimby E; Li Y; Palomba ML; Qiu L; Shadman M; Abeykoon JP; Sarosiek S; Vos J; Yi S; Stephens D; Roos-Weil D; Roccaro AM; Morel P; Munshi NC; Anderson KC; San-Miguel J; Garcia-Sanz R; Dimopoulos MA; Treon SP; Kersten MJ
    Semin Hematol; 2023 Mar; 60(2):118-124. PubMed ID: 37099031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
    Castillo JJ; Palomba ML; Advani R; Treon SP
    Ther Adv Hematol; 2016 Aug; 7(4):179-86. PubMed ID: 27493708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
    Sekiguchi N
    Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
    Thomas SK
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.